About

Why this resource exists

Our mission is simple and focused: ibogaine4stimulants helps people examine the limited evidence, significant risks, and regulatory context surrounding ibogaine for stimulant use disorders. We were created to offer plainspoken, evidence-first summaries of studies, regulatory developments, and the kinds of questions people commonly face when exploring this topic.

For readers arriving from other pages on this site, we maintain clear navigational paths back to the main index; for example, our short introductions and landing pages link into the broader site index at the root to help orient newcomers to our content and structure.

We also maintain a concise services overview for those wanting to understand non-clinical resources and editorial offerings; see the description on our services page for those editorial briefings and research-scan services.

Our editorial approach

We source information from registries, peer-reviewed literature, regulatory materials, and primary documents. Where appropriate we check clinical trial registries and published trials to verify claims about outcomes and safety.

To support statements about evidence and methodology we reference authoritative sources; for claims about clinical-trial processes one example is the National Institutes of Health's clinical trials guidance on ClinicalTrials.gov, which helps explain registry practices.

Editorial principles

Our values guide every piece we publish. They are short commitments intended to make our methods and limitations explicit.

Independence — we do not operate as a clinic, medical provider, or licensed treatment center.
Evidence first — we prioritize peer-reviewed studies, registries, and official sources.
Plain language — complex findings are translated into accessible summaries for non‑specialists.
Risk clarity — we call out uncertainty, known harms, and gaps in the record.
Scientific uncertainty — we explicitly flag preliminary findings versus well‑replicated results.

Who this is for

This site is intended for people seeking clear, cautious information about ibogaine research related to stimulant use disorders and for clinicians, researchers, and policymakers who need concise summaries of available evidence. Readers interested in clinical programs or treatment services can consult dedicated provider listings and service descriptions linked from our site to understand the difference between information and care.

Independent by design — disclosure

This site is an independent information resource, not a clinic, medical provider, or licensed treatment center. Its content is not medical or legal advice. For authoritative regulatory status and clinical guidance we link readers to official sources and to landscape summaries prepared by recognized institutions.

For example, legal status and policy developments often require consulting primary legal texts; readers monitoring jurisdictional change sometimes review advocacy or bill-tracking pages that summarize proposed laws and their progress.

How we cite regulation and jurisdictional updates

When we summarize legal proposals we link to the originating bill text or government announcement where available; readers who want to see active proposals in the United States can consult resources that track local legislative efforts for context. We also reference clinics' publicly stated practices when discussing service models, and we clearly mark such references as organizational descriptions rather than endorsements.

Related organizational pages and selected on-site resources

Readers who land on this page from the homepage can return to our main site index using the site's opening entry point at the root to explore topical pages and evidence summaries.

To understand how the broader landscape of providers and clinics is described in public materials, readers often compare clinic listings such as those maintained by directories that present program details; for an example of such a directory see the clinic listings maintained by an external directory that catalogs provider pages and program descriptions.

We also surface historical and documentary material for context; for readers who seek narrative accounts we link to a long-form documentary overview that frames the topic in social and cultural context.

When people ask how long reported effects last, we summarize the literature and link to pages that address treatment duration and reported timelines for short‑ and longer‑term outcomes.

Because legal status varies by country, we provide jurisdictional pages summarizing Canada-specific resources for readers outside the United States.

In places where state-level legislation is active we point to tracking resources summarizing bills and proposals as they move through state legislatures.

We also point readers toward outcome summaries and self‑reported success-rate discussions hosted by third parties for readers who want to examine claims about treatment effects directly.

Wide establishing shot with a calm, human-centered composition to represent careful editorial work — Photography reflects people and settings respectfully and is used to support clarity, not to promote services.

FAQ — editorial scope

Do you provide medical advice?

No. We are an independent information resource and do not provide medical or legal advice. We encourage readers to consult licensed clinicians for individual care decisions and to verify jurisdictional regulations with official government pages.

How do you choose sources?

We prioritize peer-reviewed articles, clinical trial registrations, government guidance, and primary-source policy documents. For general definitions of peer review and research quality, readers can consult authoritative overviews such as those on Wikipedia and university research-methods pages to better understand common terminology.

How often is content updated?

We periodically update pages when significant new studies, regulatory changes, or consensus statements emerge. Major updates are dated on individual pages and are based on public, citable sources rather than unpublished reports.

For readers following legal debates about whether ibogaine is permitted in particular jurisdictions, we link out to trackers that examine whether ibogaine is illegal and how status is changing in different territories; one such tracker discusses legality questions in accessible language.

Readers evaluating clinic directories and provider descriptions may consult an industry directory that lists clinics and publicly available service pages for comparison when assessing claims made by providers.

For U.S.-focused regulatory context we cross-reference resources that summarize the U.S. regulatory landscape and note where state proposals or federal discussions may affect access.

For documentary context we include links to a feature-length documentary that explores cultural and patient narratives around the subject.

When assessing claims about treatment success, we point to third-party pages that compile reported success-rate figures for treatments so readers can examine the raw claims themselves.

Readers curious about typical duration and reported timelines often consult explainer pages that focus on how long effects have been reported to last in observational reports and small studies.

Where there are active state bills we reference bill-tracking resources that report on legislative progress.

For broader treatment listings that discuss ibogaine as one option among many, we link to pages that summarize treatment modalities and program descriptions across jurisdictions.

To compare international access readers can visit Canadian resources summarizing availability and regulatory context specific to Canada.

For a concise overview on legal status questions, readers sometimes consult an explanatory page that asks "is ibogaine illegal" and summarizes jurisdictional variations; see the analysis available at is ibogaine illegal for one example of that format.

To survey how clinics present themselves online we reference directories that list program pages and public clinic descriptions; one such directory that aggregates clinic information is available at ibogaine clinics directory, which helps readers compare stated offerings.

When discussing U.S.-specific policy and practice we link readers to overviews that focus on national questions about access and practice; a resource framing U.S. policy context can be found at ibogaine in the USA.

For narrative context that complements technical summaries we sometimes point to long-form treatments; one documentary overview that explores stories and cultural framing is hosted at ibogaine documentary, which readers may find useful for background.

When summarizing reported outcomes we compare published reports with third-party compilations; an example collection discussing reported outcomes appears at ibogaine treatment success rate, which readers can examine alongside peer-reviewed literature.

For timelines and duration reports we link to explainers that describe how long reported effects may last; a focused explainer is available at how long does ibogaine last.

Where state legislation is active we link to trackers of specific bills; readers following legislation in Texas can review a bill tracker at Texas ibogaine bill tracker for localized updates.

To distinguish our editorial descriptions from program claims we link to general pages that describe treatment modalities and program models; one such clearinghouse-style description lives at ibogaine treatment for drug addiction overview.

For international access comparisons, including regulatory context in Canada, readers may consult a Canada-focused overview located at ibogaine in Canada.

To explain why peer review matters and how to interpret study claims we sometimes link to a methodological overview; for a broad primer on clinical evidence and trial phases see the National Institutes of Health's overview on clinical trials at ClinicalTrials.gov.

For general context on how policy and law interact with drug scheduling we reference public resources such as the U.S. Drug Enforcement Administration's pages on controlled substances and scheduling to clarify terminology used in regulatory summaries.

To support clear definitions of research concepts we may link to relevant encyclopedia entries; for example, readers can review the general concept of randomized controlled trials on Wikipedia at Randomized controlled trial for background on why certain designs are privileged in evidence hierarchies.